Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of KIAA1531 protein expression
    Publication number: 20040023378
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ming-Yi Chiang, Eric G. Marcusson, Kenneth W. Dobie
  • Antisense modulation of PPP3CB expression
    Publication number: 20040023382
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPP3CB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP3CB. Methods of using these compounds for modulation of PPP3CB expression and for treatment of diseases associated with expression of PPP3CB are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of PPP2R1A expression
    Publication number: 20040023381
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPP2R1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP2R1A. Methods of using these compounds for modulation of PPP2R1A expression and for treatment of diseases associated with expression of PPP2R1A are provided.
    Type: Application
    Filed: July 30, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Antisense modulation of LIM domain kinase 1 expression
    Publication number: 20040014047
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of LIM domain kinase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding LIM domain kinase 1. Methods of using these compounds for modulation of LIM domain kinase 1 expression and for treatment of diseases associated with expression of LIM domain kinase 1 are provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie
  • Antisense modulation of PTPRM expression
    Publication number: 20040014699
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPRM. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRM. Methods of using these compounds for modulation of PTPRM expression and for treatment of diseases associated with expression of PTPRM are provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie
  • Antisense modulation of protein kinase C-iota expression
    Publication number: 20040014049
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of protein kinase C-iota. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding protein kinase C-iota. Methods of using these compounds for modulation of protein kinase C-iota expression and for treatment of diseases associated with expression of protein kinase C-iota are provided.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of breast cancer-1 expression
    Publication number: 20040014051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of breast cancer-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding breast cancer-1. Methods of using these compounds for modulation of breast cancer-1 expression and for treatment of diseases associated with expression of breast cancer-1 are provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Vickie L. Brown-Driver, Kenneth W. Dobie
  • Antisense modulation of dual specific phosphatase 6 expression
    Publication number: 20040014048
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 6. Methods of using these compounds for modulation of dual specific phosphatase 6 expression and for treatment of diseases associated with expression of dual specific phosphatase 6 are provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Kenneth W. Dobie
  • Antisense modulation of EDG8 expression
    Publication number: 20040014050
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EDG8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG8. Methods of using these compounds for modulation of EDG8 expression and for treatment of diseases associated with expression of EDG8 are provided.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Kenneth W. Dobie
  • Antisense modulation of p21-activated kinase 2 expression
    Publication number: 20040009935
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of p21-activated kinase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p21-activated kinase 2. Methods of using these compounds for modulation of p21-activated kinase 2 expression and for treatment of diseases associated with expression of p21-activated kinase 2 are provided.
    Type: Application
    Filed: July 3, 2002
    Publication date: January 15, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of NF-kappa-B p50 subunit expression
    Publication number: 20040005569
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p50 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p50 subunit. Methods of using these compounds for modulation of NF-kappa-B p50 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p50 subunit are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of DEXRAS1 expression
    Publication number: 20040005706
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of DEXRAS1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding DEXRAS1. Methods of using these compounds for modulation of DEXRAS1 expression and for treatment of diseases associated with expression of DEXRAS1 are provided.
    Type: Application
    Filed: June 28, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Antisense modulation of TGF-beta 2 expression
    Publication number: 20040006030
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TGF-beta 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TGF-beta 2. Methods of using these compounds for modulation of TGF-beta 2 expression and for treatment of diseases associated with expression of TGF-beta 2 are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of insulin-like growth factor 2 expression
    Publication number: 20040006220
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of insulin-like growth factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding insulin-like growth factor 2. Methods of using these compounds for modulation of insulin-like growth factor 2 expression and for treatment of diseases associated with expression of insulin-like growth factor 2 are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie
  • Antisense modulation of phospholipase D2 expression
    Publication number: 20040005705
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phospholipase D2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phospholipase D2. Methods of using these compounds for modulation of phospholipase D2 expression and for treatment of diseases associated with expression of phospholipase D2 are provided.
    Type: Application
    Filed: June 20, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of SMRT expression
    Publication number: 20040005292
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SMRT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SMRT. Methods of using these compounds for modulation of SMRT expression and for treatment of diseases associated with expression of SMRT are provided.
    Type: Application
    Filed: June 17, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of cyclin-dependent kinase 4 expression
    Publication number: 20040005567
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cyclin-dependent kinase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cyclin-dependent kinase 4. Methods of using these compounds for modulation of cyclin-dependent kinase 4 expression and for treatment of diseases associated with expression of cyclin-dependent kinase 4 are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of HMG-CoA reductase expression
    Publication number: 20040006031
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of HMG-CoA reductase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding HMG-CoA reductase. Methods of using these compounds for modulation of HMG-CoA reductase expression and for treatment of diseases associated with expression of HMG-CoA reductase are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of livin expression
    Publication number: 20040005565
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Livin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Livin. Methods of using these compounds for modulation of Livin expression and for treatment of diseases associated with expression of Livin are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of geranylgeranyl diphosphate synthase 1 expression
    Publication number: 20040005570
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of geranylgeranyl diphosphate synthase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding geranylgeranyl diphosphate synthase 1. Methods of using these compounds for modulation of geranylgeranyl diphosphate synthase 1 expression and for treatment of diseases associated with expression of geranylgeranyl diphosphate synthase 1 are provided.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, C. Frank Bennett, Kenneth W. Dobie